サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1791708

生菌製剤（LBPs）およびマイクロバイオームCDMOの世界市場

Live Biotherapeutic Products and Microbiome CDMO

出版日
ページ情報
英文 108 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.90円
生菌製剤（LBPs）およびマイクロバイオームCDMOの世界市場
出版日: 2025年08月15日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 108 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

生菌製剤（LBPs）およびマイクロバイオームCDMOの世界市場は2030年までに6億2,770万米ドルに達する見込み

2024年に9,460万米ドルと推定される生菌製剤（LBPs）およびマイクロバイオームCDMOの世界市場は、分析期間2024～2030年に37.1%のCAGRで成長し、2030年には6億2,770万米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるC.difficleは、CAGR 37.7%を記録し、分析期間終了時には2億7,680万米ドルに達すると予測されます。クローン病セグメントの成長率は、分析期間中CAGR 37.6%と推定されます。

米国市場は2,490万米ドルと推定、中国はCAGR 35.1％で成長予測

米国の生菌製剤（LBPs）およびマイクロバイオームCDMO市場は2024年に2,490万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを35.1%として、2030年には予測市場規模9,340万米ドルに達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ33.9％と32.1％と予測されています。欧州では、ドイツがCAGR 25.8%で成長すると予測されています。

世界の生菌製剤（LBPs）およびマイクロバイオームCDMO市場- 主要動向と促進要因まとめ

なぜ生菌製剤（LBPs）およびマイクロバイオームCDMO市場は急拡大しているのか？

健康と疾患におけるヒトマイクロバイオームの役割に対する理解が深まるにつれ、生菌製剤（LBPs）およびマイクロバイオーム受託開発・製造機関（CDMO）の著しい成長が加速しています。治療効果をもたらす生きた微生物からなるLBPは、消化器疾患、代謝疾患、免疫疾患、神経疾患の治療で人気を集めています。マイクロバイオーム研究の進展に伴い、製薬企業はLBP開発に多額の投資を行っており、規制遵守とスケーラブルな製造を確保するために専門のCDMOのサポートが必要となっています。精密医療へのシフトと個別化されたマイクロバイオーム治療への需要も、この分野の拡大を後押ししています。さらに、FDAやEMAなどの規制機関は、LBPに関する明確なガイドラインを提供し、その商業化を加速させています。慢性疾患の蔓延と抗生物質耐性感染症の増加により、微生物学に基づく介入の必要性がさらに高まっています。微生物を標的とした治療に対する認識が消費者やヘルスケアプロバイダーの間で高まるにつれて、LBP市場は飛躍的な成長を遂げると予想されます。

生菌製剤（LBPs）およびマイクロバイオームCDMOサービスの成長を牽引する技術革新とは？

技術の進歩は、生きたバイオ治療製品の開発とスケーラビリティを大幅に向上させています。重要なブレークスルーの1つは、マイクロバイオーム解析における人工知能（AI）と機械学習の応用であり、これにより研究者は有益な細菌株をより効率的に特定できるようになりました。次世代シーケンシング（NGS）とメタゲノミクスは、微生物の多様性に関するより深い洞察を提供し、ターゲットを絞ったLBP製剤の設計を可能にしています。発酵技術とバイオプロセスの革新により、大規模生産が改善され、生きた微生物治療薬の安定した品質と生存性が確保されています。凍結乾燥やカプセル化技術も安定性と保存性を向上させ、微生物の生存率に関連する課題に対処しています。さらにマイクロバイオームCDMOは、自動化された製造システムとリアルタイムの品質管理分析を統合し、製造プロセスを最適化しています。機能性を強化したプロバイオティクスを設計するための合成生物学の利用は、LBPの応用の可能性をさらに広げています。継続的な調査と技術革新により、生きたバイオ治療製品はより安全で、より効果的で、商業的に実行可能な規模になりつつあります。

消費者動向と業界連携は市場をどのように形成しているか？

微生物に基づく療法やプロバイオティクス主導の健康ソリューションに対する消費者の需要の高まりが、生菌製剤市場を再形成しています。消費者は腸の健康と免疫、メンタルヘルス、代謝バランスとの関連性をますます優先するようになっており、微生物に基づく介入への関心の高まりにつながっています。個別化プロバイオティクス・レジメンやマイクロバイオーム検査キットなどのDTC（Direct-to-Consumer）マイクロバイオーム・ソリューションも人気を集めており、市場拡大に拍車をかけています。製薬企業、バイオテクノロジー企業、CDMOの業界連携が研究開発を加速させ、マイクロバイオーム療法の迅速な商業化につながっています。規制当局はLBPの承認プロセスを合理化し、市場への迅速な参入と消費者のアクセスを促進しています。さらに、マイクロバイオーム研究の新興企業に対するベンチャーキャピタルやプライベートエクイティ投資の増加により、さらなるイノベーションのための資金が供給されています。消費者が科学的裏付けのあるマイクロバイオーム解決策を求め続け、業界の利害関係者が戦略的パートナーシップを築く中、生きたバイオ治療製品市場は持続的な成長を遂げると予想されます。

生菌製剤（LBPs）およびマイクロバイオームCDMO市場を促進する主な成長要因は何か？

生菌製剤（LBPs）およびマイクロバイオームCDMO市場の成長は、慢性疾患の有病率の上昇、マイクロバイオーム調査への投資の増加、規制枠組みの進化など、複数の要因によってもたらされます。主な促進要因の1つは、炎症性腸疾患（IBD）、肥満、代謝異常などの疾患への対応におけるLBPの役割の拡大です。マイクロバイオームに基づく介入の有効性を裏付ける臨床エビデンスの蓄積は、製薬会社による製品開発の加速化を促しています。マイクロバイオームCDMOの関与は、LBPのスケーラブルで高品質な生産を保証し、より広範な採用を可能にする上で極めて重要です。さらに、合成生物学と生物工学の進歩により、微生物株の選択が最適化され、治療効果が向上しています。微生物叢に基づく精密医療の台頭も、研究者が個々の微生物叢組成に基づく標的療法を開発していることから、市場の成長に寄与しています。腸の健康に対する消費者の意識の高まりは、プロバイオティクスに基づく治療を推進する政府の取り組みと相まって、市場の拡大をさらに後押ししています。継続的な技術革新と投資により、生菌製剤（LBPs）およびマイクロバイオームCDMO業界は大きな成長を遂げ、現代のヘルスケアと治療アプローチを変革する態勢が整っています。

セグメント

アプリケーション（C.difficle、クローン病、IBS、糖尿病、その他）

調査対象企業の例

  • 4D Pharma plc
  • Arrant Bio
  • Assembly Biosciences, Inc.
  • Bacthera
  • Biose Industrie
  • Cerbios-Pharma SA
  • Freya Biosciences
  • Genetic Analysis
  • Genome & Company
  • Inpac Probiotics
  • Lallemand Health Solutions
  • List Biological Laboratories, Inc.
  • Lonza Group
  • Microbiotica
  • NIZO Food Research
  • Quay Pharmaceuticals
  • Rebiotix Inc.（A Ferring Company）
  • Seres Therapeutics
  • Siolta Therapeutics
  • Wacker Biotech

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP31868

Global Live Biotherapeutic Products and Microbiome CDMO Market to Reach US$627.7 Million by 2030

The global market for Live Biotherapeutic Products and Microbiome CDMO estimated at US$94.6 Million in the year 2024, is expected to reach US$627.7 Million by 2030, growing at a CAGR of 37.1% over the analysis period 2024-2030. C.difficle, one of the segments analyzed in the report, is expected to record a 37.7% CAGR and reach US$276.8 Million by the end of the analysis period. Growth in the Crohn's Disease segment is estimated at 37.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$24.9 Million While China is Forecast to Grow at 35.1% CAGR

The Live Biotherapeutic Products and Microbiome CDMO market in the U.S. is estimated at US$24.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$93.4 Million by the year 2030 trailing a CAGR of 35.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 33.9% and 32.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 25.8% CAGR.

Global Live Biotherapeutic Products and Microbiome CDMO Market - Key Trends & Drivers Summarized

Why Is the Market for Live Biotherapeutic Products and Microbiome CDMO Expanding Rapidly?

The increasing understanding of the human microbiome’s role in health and disease has fueled significant growth in live biotherapeutic products (LBPs) and microbiome contract development and manufacturing organizations (CDMOs). LBPs, which consist of living microorganisms offering therapeutic benefits, are gaining traction in treating gastrointestinal, metabolic, immunological, and neurological disorders. As microbiome research advances, pharmaceutical companies are heavily investing in LBP development, necessitating the support of specialized CDMOs to ensure regulatory compliance and scalable manufacturing. The shift toward precision medicine and the demand for personalized microbiome-based therapies are also driving the expansion of the sector. Additionally, regulatory agencies such as the FDA and EMA are providing clearer guidelines for LBPs, accelerating their commercialization. The growing prevalence of chronic diseases and the rise in antibiotic-resistant infections have further solidified the need for microbiome-based interventions. As awareness of microbiome-targeted treatments rises among consumers and healthcare providers, the LBP market is expected to witness exponential growth.

What Innovations Are Driving Growth in Live Biotherapeutics and Microbiome CDMO Services?

Technological advancements are significantly enhancing the development and scalability of live biotherapeutic products. One of the key breakthroughs is the application of artificial intelligence (AI) and machine learning in microbiome analysis, enabling researchers to identify beneficial bacterial strains more efficiently. Next-generation sequencing (NGS) and metagenomics are providing deeper insights into microbial diversity, allowing for the design of targeted LBP formulations. Innovations in fermentation technology and bioprocessing are improving large-scale production, ensuring consistent quality and viability of live microbial therapeutics. Freeze-drying and encapsulation techniques are also improving stability and shelf-life, addressing challenges associated with microbial viability. Additionally, microbiome CDMOs are integrating automated manufacturing systems and real-time quality control analytics to optimize production processes. The use of synthetic biology to engineer probiotics with enhanced functionalities is further expanding the potential applications of LBPs. With continued research and innovation, live biotherapeutic products are becoming safer, more effective, and commercially viable at scale.

How Are Consumer Trends and Industry Collaborations Shaping the Market?

The rising consumer demand for microbiome-based therapies and probiotic-driven health solutions is reshaping the live biotherapeutic products market. Consumers are increasingly prioritizing gut health and its connection to immunity, mental health, and metabolic balance, leading to heightened interest in microbiome-based interventions. Direct-to-consumer (DTC) microbiome solutions, such as personalized probiotic regimens and microbiome testing kits, are also gaining popularity, fueling market expansion. Industry collaborations between pharmaceutical companies, biotech firms, and CDMOs are accelerating research and development efforts, leading to faster commercialization of microbiome-based therapies. Regulatory agencies are streamlining approval processes for LBPs, facilitating quicker market entry and greater consumer access. Additionally, increased venture capital and private equity investments in microbiome research startups are providing funding for further innovations. As consumers continue to seek science-backed microbiome solutions, and industry stakeholders forge strategic partnerships, the live biotherapeutic products market is expected to experience sustained growth.

What Are the Key Growth Drivers Fueling the Live Biotherapeutic Products and Microbiome CDMO Market?

The growth in the live biotherapeutic products and microbiome CDMO market is driven by multiple factors, including the rising prevalence of chronic diseases, increasing investments in microbiome research, and evolving regulatory frameworks. One of the primary drivers is the expanding role of LBPs in addressing conditions such as inflammatory bowel disease (IBD), obesity, and metabolic disorders. The growing body of clinical evidence supporting the efficacy of microbiome-based interventions is prompting pharmaceutical companies to accelerate product development. The involvement of microbiome CDMOs is crucial in ensuring scalable, high-quality production of LBPs, enabling their broader adoption. Additionally, advancements in synthetic biology and bioengineering are optimizing microbial strain selection, enhancing therapeutic efficacy. The emergence of microbiome-based precision medicine is also contributing to market growth, as researchers develop targeted therapies based on individual microbiota compositions. Increasing consumer awareness of gut health, coupled with government initiatives to promote probiotic-based treatments, is further supporting the expansion of the market. With ongoing innovation and investment, the live biotherapeutic products and microbiome CDMO industry is poised for significant growth, transforming modern healthcare and therapeutic approaches.

SCOPE OF STUDY:

The report analyzes the Live Biotherapeutic Products and Microbiome CDMO market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Application (C.difficle, Crohn's Disease, IBS, Diabetes, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 36 Featured) -

  • 4D Pharma plc
  • Arrant Bio
  • Assembly Biosciences, Inc.
  • Bacthera
  • Biose Industrie
  • Cerbios-Pharma SA
  • Freya Biosciences
  • Genetic Analysis
  • Genome & Company
  • Inpac Probiotics
  • Lallemand Health Solutions
  • List Biological Laboratories, Inc.
  • Lonza Group
  • Microbiotica
  • NIZO Food Research
  • Quay Pharmaceuticals
  • Rebiotix Inc. (A Ferring Company)
  • Seres Therapeutics
  • Siolta Therapeutics
  • Wacker Biotech

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Live Biotherapeutic Products and Microbiome CDMO - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Clinical Validation of Microbiome-Based Therapies Throws the Spotlight on Live Biotherapeutic Product Development
    • Surge in Investment Across Microbiome Startups Drives Demand for End-to-End CDMO Services
    • OEM Focus on cGMP-Compliant Manufacturing of Anaerobic Organisms Strengthens Scale-Up Capabilities
    • Expansion of IND-Focused Microbial Therapeutics Spurs Growth in Clinical-Grade Microbiome CDMO Pipelines
    • Regulatory Recognition of Live Biotherapeutics as a Distinct Drug Class Propels CDMO Specialization
    • OEM Development of Freeze-Drying, Spray-Drying, and Encapsulation Technologies Enhances Strain Viability and Shelf Life
    • Growth in Fecal Microbiota Transplant (FMT) Alternatives Accelerates Innovation in Defined Microbial Consortia
    • OEM Emphasis on Controlled Fermentation and Cell Banking Enhances Batch Consistency and Regulatory Compliance
    • Rising Incidence of Chronic Inflammatory and GI Disorders Strengthens Demand for Live Microbial Drug Candidates
    • OEM Integration of Genomic and Metabolomic Tools in CDMO Workflows Enhances Product Characterization
    • Growth in Oncology and Immunotherapy Co-Therapies Drives Expansion of Microbiome-Based Adjuvant Therapies
    • OEM Investment in Targeted Delivery Mechanisms Expands Application in Non-GI Therapeutic Areas
    • Expansion of CDMO Services to Include Regulatory Filing and Stability Testing Strengthens Strategic Partnerships
    • OEM Collaboration With Academic Spin-Offs and Platform Companies Fuels Early-Stage Development Pipelines
    • Emerging Interest in Vaginal, Skin, and Nasal Microbiome Therapeutics Broadens CDMO Capabilities
    • Rising Demand for Personalized Microbial Therapeutics Supports N-of-1 and Modular GMP Production Models
    • OEM Emphasis on Cryopreservation and Room-Temperature Stability Drives Formulation Innovation
    • Growth in Companion Animal Microbiome Health Products Opens Veterinary CDMO Service Channels
    • Regulatory Alignment Across US and EU for Live Biotherapeutic Clinical Trials Encourages Global Development Programs
    • Focus on Process Development and Tech Transfer Efficiency Strengthens CDMO Differentiation
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Live Biotherapeutic Products and Microbiome CDMO Market Analysis of Annual Sales in US$ for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Live Biotherapeutic Products and Microbiome CDMO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Live Biotherapeutic Products and Microbiome CDMO by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for C.difficle by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for C.difficle by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Crohn's Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Crohn's Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for IBS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for IBS by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Diabetes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Others by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Live Biotherapeutic Products and Microbiome CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for Live Biotherapeutic Products and Microbiome CDMO by Application - C.difficle, Crohn's Disease, IBS, Diabetes and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 15: USA 6-Year Perspective for Live Biotherapeutic Products and Microbiome CDMO by Application - Percentage Breakdown of Value Sales for C.difficle, Crohn's Disease, IBS, Diabetes and Others for the Years 2025 & 2030
  • CANADA
    • TABLE 16: Canada Recent Past, Current & Future Analysis for Live Biotherapeutic Products and Microbiome CDMO by Application - C.difficle, Crohn's Disease, IBS, Diabetes and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 17: Canada 6-Year Perspective for Live Biotherapeutic Products and Microbiome CDMO by Application - Percentage Breakdown of Value Sales for C.difficle, Crohn's Disease, IBS, Diabetes and Others for the Years 2025 & 2030
  • JAPAN
    • Live Biotherapeutic Products and Microbiome CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 18: Japan Recent Past, Current & Future Analysis for Live Biotherapeutic Products and Microbiome CDMO by Application - C.difficle, Crohn's Disease, IBS, Diabetes and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 19: Japan 6-Year Perspective for Live Biotherapeutic Products and Microbiome CDMO by Application - Percentage Breakdown of Value Sales for C.difficle, Crohn's Disease, IBS, Diabetes and Others for the Years 2025 & 2030
  • CHINA
    • Live Biotherapeutic Products and Microbiome CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 20: China Recent Past, Current & Future Analysis for Live Biotherapeutic Products and Microbiome CDMO by Application - C.difficle, Crohn's Disease, IBS, Diabetes and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 21: China 6-Year Perspective for Live Biotherapeutic Products and Microbiome CDMO by Application - Percentage Breakdown of Value Sales for C.difficle, Crohn's Disease, IBS, Diabetes and Others for the Years 2025 & 2030
  • EUROPE
    • Live Biotherapeutic Products and Microbiome CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 22: Europe Recent Past, Current & Future Analysis for Live Biotherapeutic Products and Microbiome CDMO by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 23: Europe 6-Year Perspective for Live Biotherapeutic Products and Microbiome CDMO by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 24: Europe Recent Past, Current & Future Analysis for Live Biotherapeutic Products and Microbiome CDMO by Application - C.difficle, Crohn's Disease, IBS, Diabetes and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 25: Europe 6-Year Perspective for Live Biotherapeutic Products and Microbiome CDMO by Application - Percentage Breakdown of Value Sales for C.difficle, Crohn's Disease, IBS, Diabetes and Others for the Years 2025 & 2030
  • FRANCE
    • Live Biotherapeutic Products and Microbiome CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 26: France Recent Past, Current & Future Analysis for Live Biotherapeutic Products and Microbiome CDMO by Application - C.difficle, Crohn's Disease, IBS, Diabetes and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 27: France 6-Year Perspective for Live Biotherapeutic Products and Microbiome CDMO by Application - Percentage Breakdown of Value Sales for C.difficle, Crohn's Disease, IBS, Diabetes and Others for the Years 2025 & 2030
  • GERMANY
    • Live Biotherapeutic Products and Microbiome CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 28: Germany Recent Past, Current & Future Analysis for Live Biotherapeutic Products and Microbiome CDMO by Application - C.difficle, Crohn's Disease, IBS, Diabetes and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 29: Germany 6-Year Perspective for Live Biotherapeutic Products and Microbiome CDMO by Application - Percentage Breakdown of Value Sales for C.difficle, Crohn's Disease, IBS, Diabetes and Others for the Years 2025 & 2030
  • ITALY
    • TABLE 30: Italy Recent Past, Current & Future Analysis for Live Biotherapeutic Products and Microbiome CDMO by Application - C.difficle, Crohn's Disease, IBS, Diabetes and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 31: Italy 6-Year Perspective for Live Biotherapeutic Products and Microbiome CDMO by Application - Percentage Breakdown of Value Sales for C.difficle, Crohn's Disease, IBS, Diabetes and Others for the Years 2025 & 2030
  • UNITED KINGDOM
    • Live Biotherapeutic Products and Microbiome CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 32: UK Recent Past, Current & Future Analysis for Live Biotherapeutic Products and Microbiome CDMO by Application - C.difficle, Crohn's Disease, IBS, Diabetes and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 33: UK 6-Year Perspective for Live Biotherapeutic Products and Microbiome CDMO by Application - Percentage Breakdown of Value Sales for C.difficle, Crohn's Disease, IBS, Diabetes and Others for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 34: Rest of Europe Recent Past, Current & Future Analysis for Live Biotherapeutic Products and Microbiome CDMO by Application - C.difficle, Crohn's Disease, IBS, Diabetes and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Rest of Europe 6-Year Perspective for Live Biotherapeutic Products and Microbiome CDMO by Application - Percentage Breakdown of Value Sales for C.difficle, Crohn's Disease, IBS, Diabetes and Others for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Live Biotherapeutic Products and Microbiome CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 36: Asia-Pacific Recent Past, Current & Future Analysis for Live Biotherapeutic Products and Microbiome CDMO by Application - C.difficle, Crohn's Disease, IBS, Diabetes and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Asia-Pacific 6-Year Perspective for Live Biotherapeutic Products and Microbiome CDMO by Application - Percentage Breakdown of Value Sales for C.difficle, Crohn's Disease, IBS, Diabetes and Others for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 38: Rest of World Recent Past, Current & Future Analysis for Live Biotherapeutic Products and Microbiome CDMO by Application - C.difficle, Crohn's Disease, IBS, Diabetes and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Rest of World 6-Year Perspective for Live Biotherapeutic Products and Microbiome CDMO by Application - Percentage Breakdown of Value Sales for C.difficle, Crohn's Disease, IBS, Diabetes and Others for the Years 2025 & 2030

IV. COMPETITION